The serotonin syndrome: Definition and eause

References

• Braitberg G. Serotonin syndrome. Med J Aust 1994; 160: 527–8
   PubMedGoogle Scholar
• Kline S. S., Mauro L. S., Scala-Barnett D. M., Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 1989; 8: 510–4
   PubMedGoogle Scholar
• Lenzi A., Raffaelli S., Marazziti D. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder; following inappropriate increase in fluvoxamine dosage. Pharmacopsych 1993; 26: 100–1
   PubMedGoogle Scholar
• Lejoyeux M., Fineyre F. The serotonin syndrome. Am J Psychiatry 1992; 149: 1410–1
   PubMed Web of Science ®Google Scholar
• Price L. H., Charney D. Serotonin syndrome. Am J Psychiatry 1992; 149: 1116–7
   PubMedGoogle Scholar
• Ooi T. K. The serotonin syndrome. Anaesthesia 1991; 46: 507–8
   PubMed Web of Science ®Google Scholar
• Halman M., Goldbloom D. S. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 1990; 28: 518–21
   PubMed Web of Science ®Google Scholar
• Goldberg R. J., Huk M. Serotonin syndrome from traxodone and buspirone. Psychosomatics 1992; 33: 235–6
   PubMedGoogle Scholar
• Dursun M. S., Mathew V. M., Reveley M. A. Toxic serotonin syndrome after fluoxetine plus carbamaze-pine. Lancet 1993; 342: 442–3
   PubMed Web of Science ®Google Scholar
• Baloh R. W., Dietz J., Spooner J. W. Myoclonus and ocular oscillations induced by L-tryptophan. Ann Neurol 1982; 11: 95–7
   PubMedGoogle Scholar
• Insel T. R., Roy B. V., Cohen R. M., Murphy D. L. Possible development of the serotonin syndrome in man. Am J Psychiatry 1982; 139: 954–5
   PubMed Web of Science ®Google Scholar
• Thomas J. M., Rubin E. H. Case report of a toxic reaction from a combination of tryptophan and phenelzine. Am J Psychiatry 1984; 141: 281–3
   PubMed Web of Science ®Google Scholar
• Pope H. G., Jonas J. M., Hudson J. T., Kafka M. P. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptohan. Am J Psychiatry 1985; 142: 491–2
   PubMed Web of Science ®Google Scholar
• Levy A. B., Bucher P., Votolato N. Myoclonus hy-perreflexia and diaphoresis in patient on phenelzine-tryptophan combination treatment. Can J Psychiatry 1985; 30: 434–6
   PubMedGoogle Scholar
• Guze B. H., Baxter LR, Jr. The serotonin syndrome: case responsive to propranolol. J Clin Psychophar-macol 1986; 6: 119–20
   PubMed Web of Science ®Google Scholar
• Price W. A., Zimmer B., Kucas P. Serotonin syndrome: A case report. J Clin Pharmacol 1986; 26: 77–8
   PubMed Web of Science ®Google Scholar
• Steiner W., Fontaine R. Toxic reaction following the combined administration fluoxetine and L-tryptophan: Five case reports. Biol Psychiatry 1986; 21: 1067–71
   PubMed Web of Science ®Google Scholar
• Sandyk R. L-Dopa induced serotonin syndrome- in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol 1986; 6: 194–5
   PubMed Web of Science ®Google Scholar
• Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; 2: 850
   PubMed Web of Science ®Google Scholar
• Feighner J. P., Boyer W. F., Tyler D. L., Neborsky R. J. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222–5
   PubMed Web of Science ®Google Scholar
• Klee B., Kronig M. H. Case report of probable sertra-line-induced akathisia. Am J Psychiatry 1993; 150: 986–7
   PubMedGoogle Scholar
• Brennan D., Manus M. M., Howe J., McLoughlin J. Neuroleptic malignant syndrome without neuroleptics. Br J Psychiatry 1988; 152: 578–9
   PubMedGoogle Scholar
• Spigset O., Mjömdal T., Lövheim O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ 1993; 306: 248
   PubMed Web of Science ®Google Scholar
• Muly C. E., McDonald W., Steffens D., Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry 1993; 150: 1565
   PubMed Web of Science ®Google Scholar
• Nierenberg D. W., Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993; 53: 84–8
   PubMedGoogle Scholar
• Nimmo S. M., Kennedy B. W., Tullett W. M., Blyth A. S., Dougall J. R. Drug-induced hyperthermia. Anaesthesia 1993; 48: 892–5
   PubMed Web of Science ®Google Scholar
• Neuvonen J. P., Pohjola-Sintonen, Tacke U., Vuori E. Five fatal cases of serotonin syndrome after moc-lobemide—citalopram or moclobemide—clomipramine overdose. Lancet 1993; 342
   Google Scholar
• Brodribb T. R., Downey M., Gilbar P. J. Efficacy and adverse effects of moclobemide. Lancet 1994; 343: 475
   PubMedGoogle Scholar
• öhman R., Spigest O. Serotonin syndrome induced by fluvoxamine—lithium interaction. Pharmaco-psychiat 1993; 26: 263–4
   PubMed Web of Science ®Google Scholar
• Kojima H., Terao T., Yoshimura R. Serotonin syndrome during clomipramine and lithium treatment. Am J Psychiatry 1993; 150: 1897
   PubMedGoogle Scholar
• Coplan J. D., Gorman J. M. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry 1993; 150: 837
   PubMed Web of Science ®Google Scholar
• Hernandez A., Montero M. N., Pla A., Villanueva E. Fatal moclobemide overdose or death caused by serotonin syndrome. J Foren Sci 1995; 40: 128–30
   PubMed Web of Science ®Google Scholar
• Graber M. A., Hoehns T. B., Perry P. J. Sertraline -phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother 1994; 28: 732–5
   PubMed Web of Science ®Google Scholar
• Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994; 24: 983–5
   PubMedGoogle Scholar
• Jahr J. S., Pisto J. D., Gitlin M. The Serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg 1994; 79: 189–91
   PubMedGoogle Scholar
• Karle J., Bjørndal F. Serotonergt syndrom. Ugeskr Laeger 1994; 157: 1204–5
   Google Scholar
• Brannan S. K., Talley B. J., Bowden C. L. Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol 1994; 14: 144–5
   PubMedGoogle Scholar
• Kaminsk C. A., Robbins M. S., Weibley R. E. Sertraline intoxication in a child. Ann Emerg Med 1994; 23: 1371–4
   PubMedGoogle Scholar
• Lappin R. I., Auchincloss E. L. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994; 331: 1021–2
   PubMed Web of Science ®Google Scholar
• Reeves R. R., Bullen J. A. Serotonin syndrome produced by paroxetin and low-dose trazodone. Psyc-homatics 1995; 36: 159–60
   PubMed Web of Science ®Google Scholar
• Cano-Muñox J. L., Montejo-Iglesias M. L., Yañez-Saez, Gálvez-Borrero I. M. Possible serotonin syndrome following the combined administration of clomipramine and alprazolam. J Clin Psychiatry 1995; 56: 122
   Google Scholar
• Skop B. P., Finkelstein J. A., Mareth T. R., Magoon M. R., Brown T. M. The serotonin syndrome associated with paroxetine, an over-the counter cold remedy, and vascular disease. Am J Emerg Med 1994; 12: 642–4
   PubMed Web of Science ®Google Scholar
• Heyland D., Sauvé M. Neuroleptic malignant syndrome without the use of neuroleptics. Can Med Assoc J 1991; 145: 817–9
   Google Scholar
• Persson R. Serotonergt syndrom—en fallbeskrivn-ing. Nord J Psychiatry 1992; 46: 117–9
   Google Scholar
• Bodner R. A., Lynch T., Lewis L., Kahn D. Serotonin syndrome. Neurology 1995; 45: 219–33
   PubMed Web of Science ®Google Scholar
• Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–13
   PubMed Web of Science ®Google Scholar
• Becker T., Komhuber J., Hofmann E., Weller M., Rupprecht C., Beckmann H. MRI white matter hy-perintensity in neuroleptic malignant syndrome (NMS)—a clue to pathogenesis. J Neural Transm [GenSect] 1992; 90: 151–9
   PubMedGoogle Scholar
• Ishiguro T., Nisijima K. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobuty-ric acid in neuroleptic malignant syndrome. XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress. Neuropsycho-pharmacology 1994; 10(No. 3S/Part 1)462S, ISSN 0893–133X.
   Google Scholar
• Yamawaki S., Hayashi T. Intercellular calcium mechanism in the pathogenesis of neuroleptic malignant syndrome. XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress. Neu-ropsychopharmacology 1994; 10(No. 3S/Part 1)465S, ISSN 0893–133X.
   Google Scholar
• Henry J. A. Serotonin syndrome. Lancet 1994; 343: 607
   PubMed Web of Science ®Google Scholar
• Lucimey L., Salazar M., Trejo E. Modulation of 5HTIA receptors in the rats treated with clonazepam. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 663–77
   PubMedGoogle Scholar
• Lucimey L. Region-selective reduction of brain serotonin turnover rate and serotonin agonist-induced behavior in mice treated with clonazepam. Pharmacol Biochem Behav 1990; 39: 671–6
   Google Scholar
• Leonard H. L., Topol D., Bukstein O., Hindmarsh D., Allan A. J., Swedo S. E. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1994; 33: 792–4
   PubMed Web of Science ®Google Scholar